Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Low-income patients' access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

I would like to receive WebMD’s Newsletter and other email updates from WebMD. What is GLP-1 and how does it work? How GLP-1 medications help with weight loss Who can benefit from GLP-1 ...

novel drugs and personalized health tools. One of the most impactful developments in recent years has been the rise of GLP-1s like semaglutide and tirzepatide — with roughly 12% of Americans ...

Kevin Lin, from Harvard Medical School in Boston, and colleagues assessed national trends and characteristics of patients with obesity who were prescribed GLP-1 RAs vs those undergoing metabolic ...

GLP-1 receptor agonists, like Wegovy and Ozempic, have taken center stage in obesity and diabetes treatment ... Food itself is one of the best therapeutic tools for long-term health — and ...

GLP-1 drugs can be prescribed for type 2 diabetes or obesity, and studies have shown they may be effective against other conditions—from polycystic ovarian syndrome (PCOS) to liver disease ...

These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion by 2031. Our report on the obesity drug market ...

HM17321 addresses a key limitation in current GLP-1-based therapies, which often lead to muscle loss as a side effect of significant weight reduction. "HM17321 is the novel concept of obesity drug ...

Study Finds Bariatric Surgery Declined With Rise in GLP-1 Drugs to Treat Obesity Oct. 25, 2024 — A new study has examined a large sample of privately insured patients with obesity and found that ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Among those states that don’t cover the ...